EPS for Intec Pharma Ltd. (NTEC) Expected At $-0.30

November 10, 2018 - By Hazel Jackson

Intec Pharma Ltd. (NASDAQ:NTEC) Logo

Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.30 EPS on November, 21.They anticipate $0.10 EPS change or 25.00 % from last quarter’s $-0.4 EPS. After having $-0.34 EPS previously, Intec Pharma Ltd.’s analysts see -11.76 % EPS growth. The stock increased 0.17% or $0.01 during the last trading session, reaching $5.89. About 126,488 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has declined 49.01% since November 11, 2017 and is downtrending. It has underperformed by 64.63% the S&P500.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $195.70 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

More recent Intec Pharma Ltd. (NASDAQ:NTEC) news were published by: Seekingalpha.com which released: “Intec Pharma: Lead Program Progressing, Continued Upside Ahead” on October 26, 2018. Also Seekingalpha.com published the news titled: “Intec Pharma completes enrollment in Phase 3 trial of AP-CD/LD for the treatment of advanced PD” on October 22, 2018. Stockhouse.com‘s news article titled: “Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update” with publication date: November 09, 2018 was also an interesting one.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>